{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:00:24Z","timestamp":1790661624586,"version":"4.1.0"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>This study aimed at establishing a mouse model of immune-related adverse in humanized BALB\/c-hPD1\/hCTLA4 mice to investigate their potential pathogenesis and explore therapeutic targets for immune-related arthritis and pneumonitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Humanized BALB\/c-hPD1\/hCTLA4 mice were injected with vehicle or collagen-specific antibodies (CA) and immune checkpoint inhibitors (ICI, ipilimumab, anti-human CTLA-4; and nivolumab, anti-human PD-1), and some mice were treated with anti-TNF-\u03b1 antibody, leading to the control, collagen antibody-induced arthritis (CAIA), CAIA+ICI and treatment groups. The severity of clinical arthritis and pneumonitis in mice was monitored longitudinally and the pathological changes in the joints and lungs were histologically analyzed and the contents of lung hydroxyproline were measured. The frequency of different subsets of T cells was analyzed by flow cytometry and multiplex immunofluorescency.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Compared with the control, the ICI group of mice developed the delayed onset of moderate degrees of arthritis while the CAIA+ICI group of mice exhibited the early onset of severe arthritis. Treatment with ICI caused severe pneumonitis, especially in the mice with CA. Flow cytometry analysis indicated a significantly higher frequency of splenic TNF-\u03b1<jats:sup>+<\/jats:sup>CD4<jats:sup>+<\/jats:sup>and TNF-\u03b1<jats:sup>+<\/jats:sup>CD8<jats:sup>+<\/jats:sup>T cells, but not other subsets of T cells tested, in the CAIA+ICI group of mice, relative to that in other groups of mice. Treatment with anti-TNF-\u03b1 significantly mitigated the severity of arthritis and pneumonitis as well as deposition of collagen in lung of mice. The treatment also decreased the frequency of TNF-\u03b1<jats:sup>+<\/jats:sup>CD4<jats:sup>+<\/jats:sup>and TNF-\u03b1<jats:sup>+<\/jats:sup>CD8<jats:sup>+<\/jats:sup>T cells as well as effector memory T cells in the periphery lymph orangs and lungs of mice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We successfully established a humanized mouse model of ICI-related severe arthritis and pneumonitis with a higher frequency of TNF-\u03b1<jats:sup>+<\/jats:sup>T cells, which were significantly mitigated by anti-TNF-\u03b1 treatment. Conceptually, ICI treatment can induce multiple autoimmune-like diseases in autoimmune-prone individuals and TNF-\u03b1<jats:sup>+<\/jats:sup>T cells may be therapeutic targets for intervention of immune-related arthritis and pneumonitis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.955812","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T08:14:02Z","timestamp":1660032842000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["TNF-\u03b1 inhibitor ameliorates immune-related arthritis and pneumonitis in humanized mice"],"prefix":"10.3389","volume":"13","author":[{"given":"Jian","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlin","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianghui","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhinan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13045-018-0578-4","article-title":"Lessons learned from the blockade of immune checkpoints in cancer immunotherapy","volume":"11","author":"Li","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.05.002","article-title":"Coinhibitory pathways in the B7-Cd28 ligand-receptor family","volume":"44","author":"Schildberg","year":"2016","journal-title":"Immunity"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2015.35","article-title":"Development of immuno-oncology drugs - from Ctla4 to Pd1 to the next generations","volume":"15","author":"Hoos","year":"2016","journal-title":"Nat Rev Drug Discovery"},{"key":"B4","doi-asserted-by":"publisher","first-page":"261","DOI":"10.21037\/atm.2016.04.01","article-title":"Harnessing the immune system to improve cancer therapy","volume":"4","author":"Papaioannou","year":"2016","journal-title":"Ann Transl Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: Understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32132","article-title":"A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors","volume":"145","author":"Arnaud-Coffin","year":"2019","journal-title":"Int J Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-Ctla-4 antibodies: Systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage iii melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage iii melanoma (Eortc 18071): A randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: A systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the society for immunotherapy of cancer (Sitc) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-Ctla-4 treatment (Checkmate 037): A randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","article-title":"Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab","volume":"76","author":"Cappelli","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: A single-centre prospective cohort study","volume":"77","author":"Kostine","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/Programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.7268","article-title":"A multidisciplinary toxicity team for cancer immunotherapy-related adverse events","volume":"17","author":"Naidoo","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-Pd-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1022","article-title":"Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer","volume":"5","author":"Simonaggio","year":"2019","journal-title":"JAMA Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"238ra70","DOI":"10.1126\/scitranslmed.3008211","article-title":"Improved survival with T cell clonotype stability after anti-Ctla-4 treatment in cancer patients","volume":"6","author":"Cha","year":"2014","journal-title":"Sci Transl Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-018-0012-z","article-title":"Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-Ctla-4 antibodies in Ctla4 humanized mice","volume":"28","author":"Du","year":"2018","journal-title":"Cell Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1835","article-title":"Ctla-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms","volume":"11","author":"Ise","year":"2010","journal-title":"Nat Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0682","article-title":"Il17a blockade successfully treated psoriasiform dermatologic toxicity from immunotherapy","volume":"7","author":"Johnson","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.it.2021.02.006","article-title":"Predicting and preventing immune checkpoint inhibitor toxicity: Targeting cytokines","volume":"42","author":"Kang","year":"2021","journal-title":"Trends Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.790051","article-title":"Immune thrombocytopenia induced by immune checkpoint inhibitrs in lung cancer: Case report and literature review","volume":"12","author":"Xie","year":"2021","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203832","article-title":"The histamine H4 receptor mediates inflammation and Th17 responses in preclinical models of arthritis","volume":"73","author":"Cowden","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107596","article-title":"Iguratimod reduces b-cell secretion of immunoglobulin to play a protective role in interstitial lung disease","volume":"97","author":"Han","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2144\/000112729","article-title":"Standardized quantification of pulmonary fibrosis in histological samples","volume":"44","author":"Hubner","year":"2008","journal-title":"Biotechniques"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2949","article-title":"Genetic subtyping and phenotypic characterization of the immune microenvironment and Myc\/Bcl2 double expression reveal heterogeneity in diffuse Large b-cell lymphoma","volume":"28","author":"Xu-Monette","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(04)00051-2","article-title":"Structural and functional analysis of the costimulatory receptor programmed death-1","volume":"20","author":"Zhang","year":"2004","journal-title":"Immunity"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/ni0502-427","article-title":"Structural mechanisms of costimulation","volume":"3","author":"Schwartz","year":"2002","journal-title":"Nat Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2021.108813","article-title":"A novel humanized model of rheumatoid arthritis associated lung disease","volume":"230","author":"Lin","year":"2021","journal-title":"Clin Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1417320112","article-title":"Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients","volume":"112","author":"Romano","year":"2015","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000289195","article-title":"Cellular mechanisms of tnf function in models of inflammation and autoimmunity","volume":"11","author":"Apostolaki","year":"2010","journal-title":"Curr Dir Autoimmun"},{"key":"B37","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrrheum.2015.169","article-title":"Tnf biology, pathogenic mechanisms and emerging therapeutic strategies","volume":"12","author":"Kalliolias","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2020.08.009","article-title":"Treatment of acute lung inflammation by pulmonary delivery of anti-Tnf-Alpha sirna with pamam dendrimers in a murine model","volume":"156","author":"Bohr","year":"2020","journal-title":"Eur J Pharm Biopharm"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211781","article-title":"Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: An open-label, non-inferiority, randomised clinical trial","volume":"77","author":"l'Ami","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B40","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1136\/annrheumdis-2017-211605","article-title":"Modification of structural lesions on mri of the sacroiliac joints by etanercept in the embark trial: A 12-week randomised placebo-controlled trial in patients with non-radiographic axial spondyloarthritis","volume":"77","author":"Maksymowych","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B41","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/pds.3409","article-title":"Association between anti-Tnf-Alpha therapy and interstitial lung disease","volume":"22","author":"Herrinton","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B42","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/intimm\/dxu102","article-title":"Anti-tnf therapy: Past, present and future","volume":"27","author":"Monaco","year":"2015","journal-title":"Int Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.2217\/imt.13.173","article-title":"Potential use of tnf-\u0391 inhibitors in systemic sclerosis","volume":"6","author":"Murdaca","year":"2014","journal-title":"Immunotherapy"},{"key":"B44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10354-015-0344-y","article-title":"Anti-tnf in rheumatoid arthritis: An overview","volume":"165","author":"Radner","year":"2015","journal-title":"Wien Med Wochenschr"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000268","article-title":"Incidence and clinical impact of anti-tnf\u03b1 treatment of severe immune checkpoint inhibitor-induced colitis in advanced melanoma: The mecolit survey","volume":"42","author":"Lesage","year":"2019","journal-title":"J immunother"},{"key":"B46","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40425-018-0346-6","article-title":"Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: Retrospective review at md Anderson","volume":"6","author":"Wang","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb7495","article-title":"Cd4(+) T cells are essential for the development of destructive thyroiditis induced by anti-Pd-1 antibody in thyroglobulin-immunized mice","volume":"13","author":"Yasuda","year":"2021","journal-title":"Sci Transl Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2022.154030","article-title":"Protective effect and mechanism of loganin and morroniside on acute lung injury and pulmonary fibrosis","volume":"99","author":"Chen","year":"2022","journal-title":"Phytomedicine"},{"key":"B49","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1161\/CIRCRESAHA.119.315428","article-title":"T-Cell-Derived mirna-214 mediates perivascular fibrosis in hypertension","volume":"126","author":"Nosalski","year":"2020","journal-title":"Circ Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.120796","article-title":"Pulmonary myeloid cell uptake of biodegradable nanoparticles conjugated with an anti-fibrotic agent provides a novel strategy for treating chronic allergic airways disease","volume":"273","author":"Chakraborty","year":"2021","journal-title":"Biomaterials"},{"key":"B51","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.138.6.1786","article-title":"Immunoregulatory activity of recombinant human tumor necrosis factor (Tnf)-alpha: Induction of tnf receptors on human T cells and tnf-Alpha-Mediated enhancement of T cell responses","volume":"138","author":"Scheurich","year":"1987","journal-title":"J Immunol"},{"key":"B52","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.140.2.531","article-title":"Enhancement of antigen- and mitogen-induced human T lymphocyte proliferation by tumor necrosis factor-alpha","volume":"140","author":"Yokota","year":"1988","journal-title":"J Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2016.08.003","article-title":"Tnf activity and T cells","volume":"101","author":"Mehta","year":"2018","journal-title":"Cytokine"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.3390\/ijms22052719","article-title":"The role of tumor necrosis factor alpha (Tnf-\u0391) in autoimmune disease and current tnf-\u0391 inhibitors in therapeutics","volume":"22","author":"Jang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1902\/jop.2014.140194","article-title":"Periodontal and serum protein profiles in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitor adalimumab","volume":"85","author":"Kobayashi","year":"2014","journal-title":"J periodontol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/03946320140270s103","article-title":"Adalimumab in the treatment of immune-mediated diseases","volume":"27","author":"Lapadula","year":"2014","journal-title":"Int J immunopathol Pharmacol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1162-y","article-title":"Prophylactic tnf blockade uncouples efficacy and toxicity in dual ctla-4 and pd-1 immunotherapy","volume":"569","author":"Perez-Ruiz","year":"2019","journal-title":"Nature"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00584-4","article-title":"Tnf in the era of immune checkpoint inhibitors: Friend or foe","volume":"17","author":"Chen","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s40425-019-0711-0","article-title":"Concurrent therapy with immune checkpoint inhibitors and tnfalpha blockade in patients with gastrointestinal immune-related adverse events","volume":"7","author":"Badran","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3449","article-title":"Combining nivolumab and ipilimumab with infliximab or certolizumab in patients with advanced melanoma: First results of a phase ib clinical trial","volume":"27","author":"Montfort","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-2524","article-title":"Blocking tumor necrosis factor alpha enhances Cd8 T-Cell-Dependent immunity in experimental melanoma","volume":"75","author":"Bertrand","year":"2015","journal-title":"Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1038\/s41467-017-02358-7","article-title":"Tnfalpha blockade overcomes resistance to anti-Pd-1 in experimental melanoma","volume":"8","author":"Bertrand","year":"2017","journal-title":"Nat Commun"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.955812\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T01:49:40Z","timestamp":1676339380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.955812\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,9]]},"references-count":62,"alternative-id":["10.3389\/fimmu.2022.955812"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.955812","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,9]]},"article-number":"955812"}}